Table 1 Baseline characteristics of the patients, overall and in each treatment group
| Â | Total n.49 | Exposure to TDF | Exposure to concomitant use of TDF and PI | ||||
|---|---|---|---|---|---|---|---|
| Â | Â | A TDF n.31 (63%) | B NO TDF n.18 (37%) | p | C TDF+PI n.23 (47%) | D NO TDF+PI n.26 (53%) | p |
Female n (%) | 28 (57%) | 18 (58%) | 10 (56%) | 0.86 | 12 (52%) | 16 (62%) | 0.51 |
Age Mean (SD) | 13.6 (± 2.5) | 14.0 | 13.0 | 0.18 | 14.1 (± 2.7) | 13.2(± 2.3) | 0.20 |
HIV < 50 copies/mL | 23 (47%) | 12 (39%) | 11 (61%) | 0.13 | 9 (39%) | 14 (54%) | 0.30 |
CD4% (SD) | 27.1 (± 10.2) | 24.7 (± 10.4) | 31.8 (± 8.3) | 0.04 | 23.6 (± 10.5) | 30.7 (± 8.8) | 0.02 |
Ethnicity (Africa) | 8 (16%) | 3 (10%) | 5 (28%) | 0.10 | 2(9%) | 6 (23%) | 0.17 |
eGFR at baseline median ml/min per 1.73 m2(IQR) | 143.6 (124.5-167.4 | 143.6 (123.7-165.4) | 147.5 (124.5-169.6) | 0.48* | 135.0 (122.2-156.0) | 152.6 (128.0-169.6) | 0.14* |
Phosphatemia at baseline Median mg/dl (IQR) | 4.4 (3.8-5.0) | 4.4 (3.8-5.0) | 4.7 (3.8-5.2) | 0.30* | 4.4 (3.9-5.0) | 4.5 (3.8-5.1) | 0.44* |
Years on current regimen mean (SD) | 1.11 (1,64) | 0,76 (1,30) | 1,71 (1,99) | 0.06 | 1 (1,41) | 1,21 (1,84) | 0.67 |
ART regimen | Â | Â | Â | Â | Â | Â | Â |
TDF+FTC+LPV/r | 10 (20%) | 10 (32%) | - | - | 10 (43%) | Â | - |
TDF+FTC+ATV/r | 11 (22%) | 11 (35%) | - | - | 11 (48%) | Â | - |
TDF+FTC+Other PI/r | 2 (4%) | 2 (6%) | - | - | 2 (9%) | Â | - |
ABC+3TC+LPV/r | 6 (12%) | - | 6 (33%) | - | - | 6 (23%) | - |
ABC+3TC+other PI | 4 (8%) | - | 4 (22%) | - | - | 4 (15%) | - |
3TC+ABC+EFV | 7 (14%) | - | 7 (39%) | - | - | 7 (27%) | - |
ABC+3TC+AZT | 1 (2%) | - | 1 (6%) | - | - | 1 (4%) | - |
TDF+ABC+EFV | 1 (2%) | 1 (3%) | - | - | - | 1 (4%) | - |
TDF+FTC+EFV | 7 (14%) | 7 (23%) | - | - | - | 7 (27%) | - |